Icaritin plus chemotherapy for high-risk liver cancer after surgery
Part of Cancer, Digestive system clinical trials.
This trial tests combining a natural compound (Icaritin) with standard chemotherapy (mFOLFOX) after liver cancer surgery to lower the chance of the cancer coming back. It is for patients whose cancer had certain high-risk features, like a large tumor or cancer in blood vessels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of liver cancer called hepatocellular carcinoma (HCC), and you had surgery within the last 8 weeks to remove all visible cancer.
- Your surgery completely removed the cancer (doctors call this R0 resection) and scans after surgery show no cancer left behind.
- You are in generally good health (ECOG score 0 or 1, meaning you can carry on daily activities).
- Your cancer had at least one high-risk feature: a single tumor larger than 5 cm, cancer in blood vessels, three or more tumors, a high-grade tumor (Edmondson III-IV), or a surgical margin of 1 cm or less.
- You have not had any prior treatment for liver cancer (like chemotherapy, targeted drugs, or radiation) before surgery.
- You have adequate blood counts, liver and kidney function, and no active infections (except hepatitis B or C that is being treated).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
This study compares two combinations of treatments for advanced liver cancer that cannot be removed with surgery. One group gets the standard care (TACE plus immunotherapy and targeted therapy) and the other gets the same plus an extra pill called icaritin. The goal is to see if adding icaritin improves outcomes.
This trial tests a new combination of a plant-based drug (icaritin) and two chemotherapy drugs (AG) for people with advanced pancreatic cancer who have not had treatment before. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.